These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 353381)

  • 21. Primary and secondary dapsone resistance of M. leprae in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985.
    Guelpa-Lauras CC; Cartel JL; Constant-Desportes M; Millan J; Bobin P; Guidi C; Brucker G; Flageul B; Guillaume JC; Pichet C
    Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4):672-9. PubMed ID: 3323369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dapsone resistance does not appear to be associated with a mutation in the dihydropteroate synthase-2 gene of Mycobacterium leprae.
    Gillis TP; Williams DL
    Indian J Lepr; 1999; 71(1):11-8. PubMed ID: 10439322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dynamics of establishing resistance of M. leprae to dapsone and rifampicin in Martinique].
    Constant-Desportes-Relouzat M; Grosset J; Guelpalauras CC; Salvini B; Cales-Quist D
    Acta Leprol; 1986; 4(3):293-300. PubMed ID: 3551468
    [No Abstract]   [Full Text] [Related]  

  • 24. The activity of rifabutin against Mycobacterium leprae.
    Yoder LJ; Jacobson RR; Hastings RC
    Lepr Rev; 1991 Sep; 62(3):280-7. PubMed ID: 1665534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of desoxy fructo serotonin (DFS) on the multiplication of M. leprae in mouse foot-pad.
    Balakrishnan S; Mester L; Venkataramanaiah HN; Bhatia VN
    Lepr India; 1982 Jan; 54(1):56-8. PubMed ID: 7047899
    [No Abstract]   [Full Text] [Related]  

  • 26. Multivariate analysis of the activity of rifamycins against rapidly growing Mycobacteria, to define an in vitro screening model for their activity against mycobacterium leprae.
    Pattyn SR; Hébrant F
    Arzneimittelforschung; 1980; 30(12):2099-103. PubMed ID: 7011330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increase in prevalence of leprosy caused by dapsone-resistant Mycobacterium leprae.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1982 Jan; 30(52):637-8. PubMed ID: 6798411
    [No Abstract]   [Full Text] [Related]  

  • 28. Mycobacterium leprae persisters after treatment with dapsone and rifampicin.
    Pattyn SR; Dockx P; Rollier MT; Rollier R; Saerens EJ
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):154-8. PubMed ID: 776851
    [No Abstract]   [Full Text] [Related]  

  • 29. A simple and rapid technique for the detection of rifampin resistance in Mycobacterium leprae.
    Honoré N; Perrani E; Telenti A; Grosset J; Cole ST
    Int J Lepr Other Mycobact Dis; 1993 Dec; 61(4):600-4. PubMed ID: 8151192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Sulfone-resistance of Mycobacterium leprae--monotherapy with diaminodiphenylsulfone--the value of triple-drug combinations].
    Floch HA
    Int J Lepr Other Mycobact Dis; 1986 Mar; 54(1):122-5. PubMed ID: 3519797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dapsone resistance in North India.
    Sreevatsa ; Girdhar BK; Ramu G; Desikan KV
    Indian J Lepr; 1985; 57(3):514-8. PubMed ID: 3913706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility of strains of Mycobacterium leprae isolated prior to 1977 from patients with previously untreated lepromatous leprosy.
    Shepard CC; Rees RJ; Levy L; Pattyn SR; Baohong J; Dela Cruz EC
    Int J Lepr Other Mycobact Dis; 1986 Mar; 54(1):11-5. PubMed ID: 3519796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A quantitative basis for sustainable anti-Mycobacterium leprae chemotherapy in leprosy control programs.
    Almeida JG
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):255-68. PubMed ID: 1522367
    [No Abstract]   [Full Text] [Related]  

  • 34. Mouse foot-pad studies with M. leprae--effect of desoxy fructo serotonin (DFS) and related compounds.
    Balakrishnan S; Mester L; Venkataramaniah HN; Bhatia VN
    Indian J Lepr; 1985; 57(2):323-8. PubMed ID: 3908578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dapsone-resistant Mycobacterium leprae in a patient receiving dapsone in low doses.
    Browne SG
    Int J Lepr Other Mycobact Dis; 1969; 37(3):296-301. PubMed ID: 4906048
    [No Abstract]   [Full Text] [Related]  

  • 36. The sensitivity to Dapsone (DDS) of Mycobacterium leprae from patients with and without previous treatment.
    Shepard CC; Levy L; Fasal P
    Am J Trop Med Hyg; 1969 Mar; 18(2):258-63. PubMed ID: 4888029
    [No Abstract]   [Full Text] [Related]  

  • 37. [Radioisotope labelling of the plasmatic activator of plasminogen].
    Díaz A; Claro A
    Sangre (Barc); 1982; 27(4A):479-84. PubMed ID: 6891503
    [No Abstract]   [Full Text] [Related]  

  • 38. Adenosine triphosphate content of Mycobacterium leprae from leprosy patients.
    Dhople AM
    Int J Lepr Other Mycobact Dis; 1984 Jun; 52(2):183-8. PubMed ID: 6373626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance in leprosy.
    Browne SG
    Lepr Rev; 1974 Sep; 45(3):276-8. PubMed ID: 4612275
    [No Abstract]   [Full Text] [Related]  

  • 40. Mouse foot pad technique for evaluation of drug resistance of M. leprae and other laboratory techniques to be used in leprosy control programmes.
    Pattyn SR
    Acta Leprol; 1983; 1(1):29-32. PubMed ID: 6401137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.